Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 déc. 2020 08h00 HE | Source: AC Immune SA

AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital Proprietary SupraAntigenTM platform continues to accelerate...
20 nov. 2020 08h40 HE | Source: AC Immune SA

Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors

Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 20, 2020 ...
18 nov. 2020 07h00 HE | Source: AC Immune SA

Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer

Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 18,...
13 nov. 2020 07h00 HE | Source: AC Immune SA

AC Immune Reports Q3 2020 Financial Results and Provides Business Update

Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indicationsFirst-in-class TDP-43 therapeutic and diagnostic...
12 nov. 2020 07h00 HE | Source: AC Immune SA

AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference

LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
09 nov. 2020 04h00 HE | Source: AC Immune SA

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

LAUSANNE, Switzerland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
09 oct. 2020 08h25 HE | Source: AC Immune SA

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding for the program AC Immune’s proprietary Morphomer™ platform continues accelerating...
23 sept. 2020 07h00 HE | Source: AC Immune SA

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety endpoint was met Multiple other...
11 sept. 2020 07h00 HE | Source: AC Immune SA

AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
05 août 2020 07h00 HE | Source: AC Immune SA

AC Immune Reports Q2 2020 Financial Results and Provides Business Update

Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020Top line Phase 2...

Page précédente